We’re proud to share that 4bases presented a scientific poster introducing InnoGraft — our innovative, minimally invasive solution for monitoring graft rejection in organ transplant patients. Congrats and thanks
4bases, a Swiss-based leader in innovative genetic diagnostic solutions for Next Generation Sequencing (NGS), proudly announces the launch of InnoGraft — a non-invasive, cost-effective, and highly sensitive
Organ transplantation, often the only remaining option for end-stage organ failure, is a highly complex field that presents numerous challenges. Among these, transplant rejection has long been
Myeloproliferative neoplasms (MPNs) are a group of hematological malignancies characterized by the overproduction of red blood cells, platelets, or certain white blood cells. These disorders
Hypercholesterolemia presents a high and preventable risk for premature adverse cardiovascular events. Although genetics is among its commonest causes, Familial Hypercholesterolemia (FH), which involves pathogenic
Q – Stefano: How did you like your internship at 4bases? A – Jamila: I really, really loved it. I was initially a bit worried
Thalassemia is an inherited blood disorder, which main consequence is a reduced production of hemoglobin leading to mild to severe anemia. Since the diagnosis of
Manno, Switzerland, and Vienna, Austria DATE 25.02.2025 4bases SA, a Swiss company specializing in NGS reagent kits and bioinformatics tools, and regulatory automation provider Platomics
We often think of Next-generation sequencing (NGS) as a powerful technology that can analyse millions of DNA variants simultaneously, making it widely used for genetic
Hereditary cardiomyopathies (CMPs) are diseases related to impaired structure and function of the heart muscles and cavities, which greatly contribute to cardiovascular mortality. These conditions